Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations

[1]  John P. Overington,et al.  The promise and peril of chemical probes. , 2015, Nature chemical biology.

[2]  John C Ashton,et al.  Drug combination studies and their synergy quantification using the Chou-Talalay method--letter. , 2015, Cancer research.

[3]  R. Muschel,et al.  Identification of vitamin B1 metabolism as a tumor-specific radiosensitizing pathway using a high-throughput colony formation screen , 2015, Oncotarget.

[4]  A. Redig,et al.  Basket trials and the evolution of clinical trial design in an era of genomic medicine. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. N. Coleman,et al.  Enhancing the efficacy of radiation therapy: premises, promises, and practicality. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Steven H. Lin,et al.  A High Content Clonogenic Survival Drug Screen Identifies MEK Inhibitors as Potent Radiation Sensitizers for KRAS Mutant Non–Small-Cell Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  Eddy S Yang,et al.  Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  Patricia Greninger,et al.  EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation. , 2014, Cancer research.

[9]  K. Williams,et al.  The meaning, measurement and modification of hypoxia in the laboratory and the clinic. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[10]  Marc Desrosiers,et al.  The Importance of Dosimetry Standardization in Radiobiology , 2013, Journal of research of the National Institute of Standards and Technology.

[11]  John Buatti,et al.  Lessons Learned from Radiation Oncology Clinical Trials , 2013, Clinical Cancer Research.

[12]  J. Bohannon.  Who's afraid of peer review? , 2013, Science.

[13]  G. Hannon,et al.  Patient-derived tumor xenografts: transforming clinical samples into mouse models. , 2013, Cancer research.

[14]  Peter Houghton,et al.  A Proposal Regarding Reporting of In Vitro Testing Results , 2013, Clinical Cancer Research.

[15]  Jean-Pierre Gillet,et al.  The clinical relevance of cancer cell lines. , 2013, Journal of the National Cancer Institute.

[16]  Sayan Mukherjee,et al.  Assessing the Radiation Response of Lung Cancer with Different Gene Mutations Using Genetically Engineered Mice , 2013, Front. Oncol..

[17]  K. Camphausen,et al.  Preclinical models in radiation oncology , 2012, Radiation Oncology.

[18]  David L. Vaux,et al.  Research methods: Know when your numbers are significant , 2012, Nature.

[19]  C. N. Coleman,et al.  NCI-RTOG Translational-Program Strategic Guidelines for the Early Stage Development of Radiosensitizers , 2012 .

[20]  S. Lazic,et al.  A call for transparent reporting to optimize the predictive value of preclinical research , 2012, Nature.

[21]  D. Esseltine,et al.  Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma , 2012, Clinical Pharmacokinetics.

[22]  C. Begley,et al.  Drug development: Raise standards for preclinical cancer research , 2012, Nature.

[23]  Mina J Bissell,et al.  The tumor microenvironment is a dominant force in multidrug resistance. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[24]  C. Koch,et al.  Mechanisms of blood flow and hypoxia production in rat 9L-epigastric tumors. , 2012, Tumor microenvironment and therapy.

[25]  J. Bonneterre,et al.  Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2 , 2012, British Journal of Cancer.

[26]  J. Settleman,et al.  EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. , 2011, Cancer research.

[27]  F. Prinz,et al.  Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.

[28]  N. Cordes,et al.  Radiobiology goes 3D: how ECM and cell morphology impact on cell survival after irradiation. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  Suzanne F. Jones,et al.  A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  K. Flatmark,et al.  Radiosensitizing drugs: lessons to be learned from the oxaliplatin story. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  I. Cuthill,et al.  Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines , 2010, British journal of pharmacology.

[32]  A. Harris,et al.  Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. , 2010, Cancer research.

[33]  Catherine C. Park,et al.  β1 integrin targeting to enhance radiation therapy , 2009, International journal of radiation biology.

[34]  S. Grant,et al.  Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma , 2009, Clinical Cancer Research.

[35]  E. Rowinsky,et al.  A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer , 2008, Clinical Cancer Research.

[36]  W. Franklin,et al.  Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Richard P. Hill,et al.  Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability , 2008, Nature Reviews Cancer.

[38]  M. Krause,et al.  EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: differential response of cancer stem cells and nontumourigenic cells? , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  D. Redelmeier,et al.  Translation of research evidence from animals to humans. , 2006, JAMA.

[40]  J. Whang‐Peng,et al.  Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma , 2006, Cancer Chemotherapy and Pharmacology.

[41]  T. Boulikas,et al.  Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study. , 2006, Anticancer research.

[42]  B. Lum,et al.  Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects , 2006, Journal of clinical pharmacology.

[43]  K. Camphausen,et al.  Orthotopic growth of human glioma cells quantitatively and qualitatively influences radiation-induced changes in gene expression. , 2005, Cancer research.

[44]  R A Knight,et al.  Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 , 2005, Cell Death and Differentiation.

[45]  N. Zandwijk,et al.  Tolerability of gefitinib in patients receiving treatment in everyday clinical practice , 2003, British Journal of Cancer.

[46]  L. Seymour,et al.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  M. Krause,et al.  In regard to Solomon et al.: EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. IJROBP 2003;55:713-723. , 2003, International journal of radiation oncology, biology, physics.

[48]  M. Krause,et al.  Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse , 2003, International journal of radiation biology.

[49]  James B. Mitchell,et al.  Development of investigational radiation modifiers. , 2003, Journal of the National Cancer Institute.

[50]  M. Trivett,et al.  EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. , 2003, International journal of radiation oncology, biology, physics.

[51]  C. Ling,et al.  Computerized Video Time-Lapse (CVTL) Analysis of Cell Death Kinetics in Human Bladder Carcinoma Cells (EJ30) X-Irradiated in Different Phases of the Cell Cycle , 2002, Radiation research.

[52]  W. Colburn,et al.  Thalidomide Dose Proportionality Assessment following Single Doses to Healthy Subjects , 2001, Journal of clinical pharmacology.

[53]  J Zoetelief,et al.  Protocol for X-ray dosimetry in radiobiology , 2001, International journal of radiation biology.

[54]  M. Ducreux,et al.  Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  W. Colburn,et al.  Single‐Dose Oral Pharmacokinetics of Three Formulations of Thalidomide in Healthy Male Volunteers , 1999, Journal of clinical pharmacology.

[56]  E. Rofstad,et al.  Orthotopic human melanoma xenograft model systems for studies of tumour angiogenesis, pathophysiology, treatment sensitivity and metastatic pattern. , 1994, British Journal of Cancer.

[57]  W. Cramp,et al.  The role of repair in radiobiology , 1989, Experientia.

[58]  B. Fertil,et al.  Mean Inactivation Dose: A Useful Concept for Intercomparison of Human Cell Survival Curves , 1984, Radiation research.

[59]  W. Dewey,et al.  In vitro systems: standardization of endpoints. , 1979, International journal of radiation oncology, biology, physics.

[60]  G. Steel,et al.  Cell Population Kinetics of a Spontaneous Rat Tumour During Serial Transplantation , 1971, British Journal of Cancer.

[61]  I. Tannock,et al.  THE RELATION BETWEEN CELL PROLIFERATION AND THE VASCULAR SYSTEM IN A TRANSPLANTED MOUSE MAMMARY TUMOUR , 2007 .

[62]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[63]  Peter Vaupel,et al.  Hypoxia in tumors: pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications. , 2014, Advances in experimental medicine and biology.

[64]  E. Giang,et al.  Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[65]  G. Wilding,et al.  A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors , 2013, Investigational New Drugs.

[66]  G. Giaccone,et al.  Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. , 2010, European journal of cancer.

[67]  J. Haveman,et al.  Clonogenic assay of cells in vitro , 2006, Nature Protocols.

[68]  D. Kerr,et al.  Single-Dose Clinical Pharmacokinetic Studies of Gefitinib , 2005, Clinical pharmacokinetics.

[69]  R A Knight,et al.  Classification of cell death: recommendations of the Nomenclature Committee on Cell Death , 2005, Cell Death and Differentiation.

[70]  R. Hoffman,et al.  Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models to obtain relevant drug evaluation data. , 1993, Anticancer research.

[71]  J. Denekamp,et al.  Cell kinetics and radiation biology. , 1986, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[72]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[73]  G. Steel,et al.  Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. , 1979, International journal of radiation oncology, biology, physics.

[74]  I. Lefkovits.  Limiting Dilution Analysis , 1979 .

[75]  H. Suit,et al.  Experimental evaluation of tumor bed effect for C3H mouse mammary carcinoma and for C3H mouse fibrosarcoma. , 1971, Radiation research.